论文部分内容阅读
目的探讨TEC(多西他赛、表柔比星、环磷酰胺)方案在乳腺癌新辅助化疗中的应用。方法选取2005年9月至2010年10月间进行新辅助化疗的乳腺癌患者187例,患者均采用TEC方案,分析该方案的疗效及不良反应。结果根据实体瘤疗效评价标准1.1(RECIST 1.1)进行评估,完全缓解(CR)23例,部分缓解(PR)113例,疾病稳定(SD)46例,疾病进展(PD)5例。新辅助化疗过程中,Ⅳ度骨髓抑制患者31例,且2例患者经过化疗药物剂量减量后持续出现Ⅳ度骨髓抑制,甚至并发严重感染,放弃新辅助化疗,进行手术治疗。结论 TEC方案对局部晚期乳腺癌行新辅助化疗,疗效确切,不良反应可以耐受。
Objective To investigate the application of TEC (docetaxel, epirubicin, cyclophosphamide) in neoadjuvant chemotherapy of breast cancer. Methods A total of 187 patients with breast cancer receiving neoadjuvant chemotherapy between September 2005 and October 2010 were enrolled in this study. All patients underwent TEC regimen to analyze the efficacy and adverse reactions of the regimen. Results According to RECIST 1.1 standard, there were 23 cases of complete remission (CR), 113 cases of partial remission (PR), 46 cases of stable disease (SD) and 5 cases of disease progression (PD). Neoadjuvant chemotherapy, 31 patients with grade Ⅳ myelosuppression, and 2 patients continued to appear Ⅳ degree myelosuppression after chemotherapy dose reduction, and even severe infection, to give up neoadjuvant chemotherapy for surgical treatment. Conclusion TEC regimen for neoadjuvant chemotherapy for locally advanced breast cancer is effective and tolerable.